New whooping cough vaccine shows promise for toddlers
NCT ID NCT07213089
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new booster vaccine called DTaPgen in 290 healthy toddlers aged 15 to 36 months. The goal was to see if it works as well as a currently licensed vaccine to protect against whooping cough, diphtheria, and tetanus. Children received a single shot, and researchers measured their immune response and any side effects.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- DTaPgen vaccine (recombinant acellular pertussis combined with diphtheria and tetanus)
- What this could lead to
- If successful, this could provide a new booster option to protect young children against whooping cough, potentially with fewer side effects than current vaccines.
- What could go wrong
- This is a mid-stage trial with only 290 toddlers, so results may not apply to all children. The vaccine may not prove as effective or safe as the licensed version in larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2/3
Runs two stages together: whether the treatment works, then large-scale confirmation.
- Participants
-
290 people
The number who actually took part.
- Started
-
Jul 2020
- Finished
-
May 2022
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
15 to 36 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Participants will be eligible for inclusion if ALL of the following criteria are met at the time of screening: 1. 15 to 36 months of age at the time of vaccination. 2. Having completed the 3-dose DTwP or 3-dose DTaP vaccination (no interchange of DTwP and DTaP during primary immunization). 3. The parents or legal guardians of the participant are able to read and write. 4. The parents or legal guardians can provide written informed consent. 5. Healthy, as established by pertinent medical history and physical examination. Exclusion Criteria: A participant with ANY of the following criteria at study entry will not be eligible for participation 1. History of any significant medical illness such as, but not limited to, immune deficiency, renal, hepatic, cardiovascular, or endocrine disorder as determined by the investigator based on medical history and physical examination. 2. History of allergy or hypersensitivity to any vaccine (including its component). 3. History of any serious adverse event or neurological adverse event after vaccination. 4. Having received only 1 or 2 doses of DTwP or DTaP (incomplete primary immunization) after birth until the study enrollment. 5. Having received the 4th dose DTwP or DTaP vaccination. 6. Having experienced a physician diagnosed diphtheria or tetanus or pertussis illness within 1 year prior to recruitment. 7. Receipt of any vaccine within 28 days prior to enrollment (3 months for live-attenuated vaccines). 8. Planning to receive tetanus, diphtheria, pertussis or planning to participate in another clinical trial during the study period (approximately 1 year). 9. Receipt of blood or blood component or immunoglobulin within 3 months prior to recruitment. 10. History of receiving any immunosuppressive drug or systemic corticosteroid (more than 0.5 mg/kg of prednisolone or equivalent for more than 14 days) within 3 months prior to recruitment. 11. Any bleeding disorder. 12. Any abnormality of splenic or thymic function. 13. Any progressive or severe neurological disorder such as seizure disorder or Guillain- Barre syndrome; 14. History of any illness including cognitive impairment and psychiatric disease that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the participants due to participation in the study. 15. Fever as defined by body temperature more than 38 degree celsius at the time of enrollment (temporary exclusion criterion).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Pertussis (whooping cough) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Kamphaengphet Hospital
Kamphaeng Phet, Changwat Kamphaeng Phet, 62000, Thailand
-
Phaholpolpayuhasena Hospital
Kanchanaburi, Kanchanaburi, 71000, Thailand
-
Vaccine Trial Centre (VTC), Faculty of Tropical Medicine, Mahidol University
Bangkok, Bangkok, 10400, Thailand
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New vaccine trial aims to shield teens and adults from whooping cough
- Thousands monitored: is the whooping cough vaccine safe in real life?
- Whooping cough vaccine safety under the microscope in thailand
- Scientists deliberately infect volunteers with whooping cough to speed up vaccine research
- Massive U.S. study to see if whooping cough vaccine is safe for pregnant women and babies
- Whooping cough vaccine safety checked in 2,700 thai moms and babies